Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset (PROST-3)

keskiviikko 11. marraskuuta 2026 päivittänyt: Tasly Biopharmaceuticals Co., Ltd.

A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset

This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Study Design: This is a multicenter, randomized, double-blind, double-dummy, standard-of-care (SOC)-controlled Phase III trial conducted at multiple centers in China. Randomization is performed using a stratified block randomization method, stratified by planned mechanical thrombectomy (2 levels: yes; no), with participants assigned in a 1:1 ratio to the rhPro-UK group or the SOC group.Treatment: Eligible and randomized participants receive the assigned investigational product as soon as possible (actual treatment initiation must be >4.5 hours and <=24 hours after stroke onset). The rhPro-UK group receives an intravenous infusion of rhPro-UK 35 mg in normal saline (15 mg as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg by intravenous infusion/pump over 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg at the start of thrombolysis. The SOC group receives an intravenous infusion of rhPro-UK placebo (same regimen) plus oral aspirin enteric-coated tablets 100-300 mg. All investigational products are administered once only; subsequent clinical antiplatelet therapy should be initiated no earlier than 24 hours after completion of the investigational product administration.Study Duration: The total duration of participation for each participant is approximately 90 days, including a screening period (pre-thrombolysis, -24 hours to 0 hour), a treatment period (thrombolysis, 0 hour), and a follow-up period (24 hours, 72 hours, Day 7, Day 30, and Day 90 after the start of thrombolysis).Statistical Considerations: The study hypothesis is based on the primary estimand. Null hypothesis H0: p1/p2 <= 1; alternative hypothesis H1: p1/p2 > 1, where p1 is the proportion of participants with an mRS score of 0-1 at 90 days in the rhPro-UK group and p2 is that in the SOC group. One interim analysis is planned, using the Lan-DeMets spending function with O'Brien-Fleming efficacy boundaries; the two-sided type I error is controlled at 0.003 for the interim analysis and 0.049 for the final analysis, maintaining an overall two-sided type I error of 0.05.Committees: An Academic Committee will be established before trial initiation to ensure the scientific feasibility of the protocol and standardization of trial conduct. An independent Clinical Events Committee (CEC) will adjudicate the type and drug-relatedness of all-cause death events within 7 days after treatment, as well as symptomatic intracranial hemorrhage (sICH). A Data Monitoring Committee (DMC) will convene regularly or as needed to perform unblinded sample size re-estimation, review safety data, and advise the sponsor on whether to continue, suspend, or stop the trial, or adjust the sample size.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

978

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kiina
        • Beijing Tiantan Hospital, Capital Medical University
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Age >=18 years, male or female;
  2. Time from stroke symptom onset to planned thrombolysis >4.5 hours and <=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well;
  3. Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke;
  4. Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume <70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL);
  5. NIHSS score of 6 to 25 (inclusive);
  6. Pre-stroke mRS score <2;
  7. No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator);
  8. The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the informed consent form.

Exclusion Criteria:

  1. Unable to complete CTP/CTA or PWI/DWI/MRA examination;
  2. Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory);
  3. Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.);
  4. Previous history of intracranial hemorrhage;
  5. Major head trauma or ischemic stroke within the past 3 months;
  6. Intracranial tumor or giant intracranial aneurysm;
  7. Intracranial or intraspinal surgery within the past 3 months;
  8. Gastrointestinal or urinary tract bleeding within the past 3 weeks;
  9. Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator);
  10. Arterial puncture at a non-compressible site within the past 1 week;
  11. Active internal bleeding;
  12. Aortic arch dissection;
  13. Bacterial endocarditis or pericarditis;
  14. Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg;
  15. Acute bleeding tendency, including platelet count <100 x 10^9/L;
  16. Treatment with low-molecular-weight heparin or heparin within 24 hours;
  17. Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours;
  18. Currently taking oral anticoagulants with prothrombin time (PT) >15 seconds or international normalized ratio (INR) >1.7;
  19. Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance;
  20. Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL);
  21. Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis;
  22. Severe renal insufficiency (eGFR <30 mL/min/1.73 m^2);
  23. Any terminal illness with a life expectancy of less than 1 year;
  24. Known hypersensitivity to rhPro-UK, the active ingredient of aspirin, or any other components of the investigational products;
  25. Pregnant or lactating women;
  26. Participation in another clinical trial within the past 1 month;
  27. Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial;

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: rhPro-UK Group

Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

rhPro-UK 35 mg dissolved in normal saline, administered intravenously as a single dose: 15 mg slow intravenous bolus over 3 minutes, followed by 20 mg intravenous infusion/pump over 30 minutes. Treatment initiation must be >4.5 hours and <=24 hours after stroke onset.

Oral placebo matching aspirin enteric-coated tablets, 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion).

Active Comparator: Standard of Care (SOC) Group

Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

Oral aspirin enteric-coated tablets 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). Subsequent clinical antiplatelet therapy is initiated no earlier than 24 hours after completion of the investigational product administration.

Placebo matching rhPro-UK for injection, dissolved in normal saline and administered intravenously with the same regimen as rhPro-UK (15 mg-equivalent slow intravenous bolus over 3 minutes, followed by 20 mg-equivalent intravenous infusion/pump over 30 minutes), single dose.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Proportion of Participants Achieving a Favorable Functional Outcome (mRS 0-1)
Aikaikkuna: 90 days after treatment

Description: Proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment.

90 days after treatment

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Distribution of mRS Scores
Aikaikkuna: 90 days after treatment

Distribution of modified Rankin Scale (mRS) scores at 90 days after treatment

90 days after treatment
Proportion of Participants Achieving Functional Independence (mRS 0-2)
Aikaikkuna: 90 days after treatment

Proportion of participants with an mRS score of 0-2 at 90 days after treatment.

90 days after treatment
Proportion of Participants With Early Neurological Improvement at 24 Hours
Aikaikkuna: 24 hours after treatment

Proportion of participants with a decrease of >=4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline, or an NIHSS score <=1, at 24 hours after treatment.

24 hours after treatment
Proportion of Participants With Neurological Improvement at Day 7
Aikaikkuna: 7 days after treatment

Proportion of participants with a decrease of >=4 points in NIHSS score from baseline, or an NIHSS score <=1, at 7 days after treatment.

7 days after treatment
Change From Baseline in NIHSS Score at 24 Hours
Aikaikkuna: Baseline and 24 hours after treatment

Change in NIHSS score from baseline at 24 hours after treatment.

Baseline and 24 hours after treatment
Change From Baseline in NIHSS Score at Day 7
Aikaikkuna: Baseline and 7 days after treatment

Change in NIHSS score from baseline at 7 days after treatment.

Baseline and 7 days after treatment
Proportion of Participants With a Barthel Index of 95-100
Aikaikkuna: 90 days after treatment

Proportion of participants with a Barthel Index score of 95-100 at 90 days after treatment.

90 days after treatment
Proportion of Participants Achieving Reperfusion at 24 Hours
Aikaikkuna: 24 hours after treatment

Proportion of participants achieving reperfusion at 24 hours after treatment, defined as a >90% reduction from baseline in the volume of tissue with tracer arrival time (Tmax) >6 seconds.

24 hours after treatment
Proportion of Participants Achieving Good Reperfusion on Angiography Before Thrombectomy
Aikaikkuna: Before mechanical thrombectomy (Day 0)

Proportion of participants achieving good reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) grade of 2b50 or higher, on angiography before thrombectomy (assessed only in participants undergoing mechanical thrombectomy).

Before mechanical thrombectomy (Day 0)
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the SITS-MOST Definition
Aikaikkuna: Within 36 hours after treatment

Incidence of symptomatic intracranial hemorrhage as defined by the SITS-MOST criteria.

Within 36 hours after treatment
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the ECASS III Definition
Aikaikkuna: Within 7 days after treatment

Incidence of symptomatic intracranial hemorrhage as defined by the ECASS III criteria.

Within 7 days after treatment
Incidence of All-Cause Mortality Within 7 Days
Aikaikkuna: Within 7 days after treatment

Incidence of death from any cause within 7 days after treatment.

Within 7 days after treatment
Incidence of All-Cause Mortality Within 90 Days
Aikaikkuna: Within 90 days after treatment
Within 90 days after treatment
Incidence of Major Bleeding Events Within 7 Days
Aikaikkuna: Within 7 days after treatment
Within 7 days after treatment
Incidence of Intracranial Hemorrhage Events Within 7 Days
Aikaikkuna: Within 7 days after treatment

Within 7 days after treatment

Within 7 days after treatment

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Maanantai 30. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. maaliskuuta 2029

Opintojen valmistuminen (Arvioitu)

Perjantai 1. kesäkuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 11. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 11. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 17. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 17. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 11. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • TSL-BIO2601-AIS24-Ⅲ
  • NMPA IND No. (Muu tunniste: 2026LP02152)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa